AMGEN REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2022. Key results include: Total revenues decreased 1% to $6.7...
Source: prnewswire.com
📰 Plexium Inc News
Page 2 - Plexium Inc News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Plexium Inc. Real-time updates on events, politics, business and more.
AMGEN REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2022. Key results include: Total revenues increased 1% to $6.6...
Puerto Rico United States Jessica Akopyan Roberta Bradway Provention Bio European Society For Medical Oncology Congress
Source: prnewswire.com
Amgen (NASDAQ:AMGN) vs. Aligos Therapeutics (NASDAQ:ALGS) Head to Head Contrast
Aligos Therapeutics (NASDAQ:ALGS – Get Rating) and Amgen (NASDAQ:AMGN – Get Rating) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings and dividends. Volatility and Risk Aligos Therapeutics has a beta of 3.52, indicating […]
United States South San Francisco Thousand Oaks Sensipar Mimpara Katholieke Universiteit Leuven Eli Lilly
Source: etfdailynews.com
Abbvie and Plexium Enter Into Multi-Target Strategic Collaboration To Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions
/PRNewswire/ -- Plexium, Inc. (Plexium) and AbbVie (NYSE: ABBV) have entered into an exclusive strategic collaboration to develop and commercialize novel...
Eric Karran Amy Conrad Percival Barretto Ko Plexium Inc Exchange Commission Targeted Protein Degradation
Source: prnewswire.com
AMGEN REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS
/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the first quarter of 2022. Key results include: Total revenues increased 6% to $6.2...
Source: prnewswire.com
AMGEN TO PRESENT LONG-TERM OUTCOMES FOR LUMAKRAS® (SOTORASIB) IN KRAS G12C-MUTATED NSCLC AT AACR 2022
/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that new data from across its oncology portfolio and pipeline will be presented at the American...
Source: prnewswire.com
Plexium Announces $102M Financing To Advance Pipeline Of Targeted Protein Degradation Therapies And Technology Platform
/PRNewswire/ -- Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the completion of an...
Source: prnewswire.com
LUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC CANCER IN CODEBREAK 100 TRIAL
/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS...
Source: prnewswire.com
LUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC CANCER IN CODEBREAK 100 TRIAL
/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS...
Source: prnewswire.com